These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38695469)

  • 1. Discovery of BIO-8169─A Highly Potent, Selective, and Brain-Penetrant IRAK4 Inhibitor for the Treatment of Neuroinflammation.
    Pfaffenbach M; Bolduc PN; Xin Z; Gao F; Evans R; Fang T; Chodaparambil JV; Henry KL; Li P; Mathieu S; Metrick C; Vera Rebollar JA; Gu RF; Mccarl CA; Silbereis J; Peterson EA
    J Med Chem; 2024 May; 67(10):8383-8395. PubMed ID: 38695469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and hit-to-lead optimization of 2,6-diaminopyrimidine inhibitors of interleukin-1 receptor-associated kinase 4.
    McElroy WT; Michael Seganish W; Jason Herr R; Harding J; Yang J; Yet L; Komanduri V; Prakash KC; Lavey B; Tulshian D; Greenlee WJ; Sondey C; Fischmann TO; Niu X
    Bioorg Med Chem Lett; 2015 May; 25(9):1836-41. PubMed ID: 25870132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Discovery of 7-Isopropoxy-2-(1-methyl-2-oxabicyclo[2.1.1]hexan-4-yl)-
    Evans R; Bolduc PN; Pfaffenbach M; Gao F; May-Dracka T; Fang T; Hopkins BT; Chodaparambil JV; Henry KL; Li P; Metrick C; Nelson A; Trapa P; Thomas A; Burkly L; Peterson EA
    J Med Chem; 2024 Mar; 67(6):4676-4690. PubMed ID: 38467640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and optimization of a potent and selective indazolamine series of IRAK4 inhibitors.
    Zhai W; Lu Y; Zhu Y; Zhou M; Ye C; Shi ZZ; Qian W; Hu T; Chen L
    Bioorg Med Chem Lett; 2021 Jan; 31():127686. PubMed ID: 33242574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Potent and Selective Pyrazolopyrimidine IRAK4 Inhibitors.
    Bryan MC; Drobnick J; Gobbi A; Kolesnikov A; Chen Y; Rajapaksa N; Ndubaku C; Feng J; Chang W; Francis R; Yu C; Choo EF; DeMent K; Ran Y; An L; Emson C; Huang Z; Sujatha-Bhaskar S; Brightbill H; DiPasquale A; Maher J; Wai J; McKenzie BS; Lupardus PJ; Zarrin AA; Kiefer JR
    J Med Chem; 2019 Jul; 62(13):6223-6240. PubMed ID: 31082230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of LC-MI-3: A Potent and Orally Bioavailable Degrader of Interleukin-1 Receptor-Associated Kinase 4 for the Treatment of Inflammatory Diseases.
    Chen L; Luo R; Ma L; Xu Y; Cao J; Jiang Z; Chen S; Huang X; Zhang M; Zheng L; Zhang Y; Yin L; Yu J; Zheng X; Zheng L; Huang P; Liang G
    J Med Chem; 2024 May; 67(10):8060-8076. PubMed ID: 38722184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Preclinical Candidate AD1058 as a Highly Potent, Selective, and Brain-Penetrant ATR Inhibitor for the Treatment of Advanced Malignancies.
    Liu Z; Jiang K; Liu Y; Li J; Huang S; Li P; Xu L; Xu X; Hu X; Zeng X; Huang Z; Zhou Y; Li J; Long K; Wang M
    J Med Chem; 2024 Aug; 67(15):12735-12759. PubMed ID: 39053006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.
    Kelly PN; Romero DL; Yang Y; Shaffer AL; Chaudhary D; Robinson S; Miao W; Rui L; Westlin WF; Kapeller R; Staudt LM
    J Exp Med; 2015 Dec; 212(13):2189-201. PubMed ID: 26621451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efforts towards the optimization of a bi-aryl class of potent IRAK4 inhibitors.
    Hanisak J; Seganish WM; McElroy WT; Tang H; Zhang R; Tsui HC; Fischmann T; Tulshian D; Tata J; Sondey C; Devito K; Fossetta J; Garlisi CG; Lundell D; Niu X
    Bioorg Med Chem Lett; 2016 Sep; 26(17):4250-5. PubMed ID: 27476420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4.
    Tumey LN; Boschelli DH; Bhagirath N; Shim J; Murphy EA; Goodwin D; Bennett EM; Wang M; Lin LL; Press B; Shen M; Frisbie RK; Morgan P; Mohan S; Shin J; Rao VR
    Bioorg Med Chem Lett; 2014 May; 24(9):2066-72. PubMed ID: 24726805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors.
    Jiang JK; Huang X; Shamim K; Patel PR; Lee A; Wang AQ; Nguyen K; Tawa G; Cuny GD; Yu PB; Zheng W; Xu X; Sanderson P; Huang W
    Bioorg Med Chem Lett; 2018 Nov; 28(20):3356-3362. PubMed ID: 30227946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation.
    Smith GF; Altman MD; Andresen B; Baker J; Brubaker JD; Chen H; Chen Y; Childers M; Donofrio A; Ferguson H; Fischer C; Fischmann TO; Gibeau C; Hicks A; Jin S; Kattar S; Kleinschek MA; Leccese E; Lesburg C; Li C; Lim J; Liu D; Maclean JKF; Mansoor F; Moy LY; Mulrooney EF; Necheva AS; Presland J; Rakhilina L; Yang R; Torres L; Zhang-Hoover J; Northrup A
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2721-2726. PubMed ID: 28501511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fragment-Based Anti-inflammatory Agent Design and Target Identification: Discovery of AF-45 as an IRAK4 Inhibitor to Treat Ulcerative Colitis and Acute Lung Injury.
    Zou Y; Wang X; Chen P; Zheng Z; Li X; Chen Z; Guo M; Zhou Y; Sun C; Wang R; Zhu W; Zheng P; Cho WJ; Cho YC; Liang G; Tang Q
    J Med Chem; 2024 Jul; 67(13):10687-10709. PubMed ID: 38913701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma.
    Chen Y; Bai G; Ning Y; Cai S; Zhang T; Song P; Zhou J; Duan W; Ding J; Xie H; Zhang H
    Eur J Med Chem; 2020 Mar; 190():112092. PubMed ID: 32014679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IRAK4 kinase activity controls Toll-like receptor-induced inflammation through the transcription factor IRF5 in primary human monocytes.
    Cushing L; Winkler A; Jelinsky SA; Lee K; Korver W; Hawtin R; Rao VR; Fleming M; Lin LL
    J Biol Chem; 2017 Nov; 292(45):18689-18698. PubMed ID: 28924041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88
    Scott JS; Degorce SL; Anjum R; Culshaw J; Davies RDM; Davies NL; Dillman KS; Dowling JE; Drew L; Ferguson AD; Groombridge SD; Halsall CT; Hudson JA; Lamont S; Lindsay NA; Marden SK; Mayo MF; Pease JE; Perkins DR; Pink JH; Robb GR; Rosen A; Shen M; McWhirter C; Wu D
    J Med Chem; 2017 Dec; 60(24):10071-10091. PubMed ID: 29172502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors.
    Bhide RS; Keon A; Weigelt C; Sack JS; Schmidt RJ; Lin S; Xiao HY; Spergel SH; Kempson J; Pitts WJ; Carman J; Poss MA
    Bioorg Med Chem Lett; 2017 Nov; 27(21):4908-4913. PubMed ID: 28947151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition.
    Telliez JB; Dowty ME; Wang L; Jussif J; Lin T; Li L; Moy E; Balbo P; Li W; Zhao Y; Crouse K; Dickinson C; Symanowicz P; Hegen M; Banker ME; Vincent F; Unwalla R; Liang S; Gilbert AM; Brown MF; Hayward M; Montgomery J; Yang X; Bauman J; Trujillo JI; Casimiro-Garcia A; Vajdos FF; Leung L; Geoghegan KF; Quazi A; Xuan D; Jones L; Hett E; Wright K; Clark JD; Thorarensen A
    ACS Chem Biol; 2016 Dec; 11(12):3442-3451. PubMed ID: 27791347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small Molecule Inhibition of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4).
    Genung NE; Guckian KM
    Prog Med Chem; 2017; 56():117-163. PubMed ID: 28314411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders.
    Chaudhary D; Robinson S; Romero DL
    J Med Chem; 2015 Jan; 58(1):96-110. PubMed ID: 25479567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.